Literature DB >> 26131359

Cancer-targeted therapies and radiopharmaceuticals.

Tilman D Rachner1, Franz Jakob2, Lorenz C Hofbauer3.   

Abstract

The treatment of bone metastases remains a clinical challenge. Although a number of well-established agents, namely bisphosphonates and denosumab, are available to reduce the occurrence of skeletal-related events, additional cancer-targeted therapies are required to improve patients' prognosis and quality of life. This review focuses on novel targets and agents that are under clinical evaluation for the treatment of malignant bone diseases such as activin A, src and endothelin-1 inhibition or agents that are clinically approved and may positively influence bone, such as the mTOR inhibitor everolimus. In addition, the potential of alpharadin, a novel radiopharmaceutical approved for the treatment of prostatic bone disease, is discussed.

Entities:  

Year:  2015        PMID： 26131359      PMCID： PMC4455688          DOI： 10.1038/bonekey.2015.76

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


  54 in total

1.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade.

Authors:  J B Nelson; S H Nguyen; J R Wu-Wong; T J Opgenorth; D B Dixon; L W Chung; N Inoue
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  The activin A-follistatin system: potent regulator of human extracellular matrix mineralization.

Authors:  Marco Eijken; Sigrid Swagemakers; Marijke Koedam; Cobie Steenbergen; Pieter Derkx; André G Uitterlinden; Peter J van der Spek; Jenny A Visser; Frank H de Jong; Huibert A P Pols; Johannes P T M van Leeuwen
Journal:  FASEB J       Date:  2007-04-20       Impact factor: 5.191

4.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

5.  Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.

Authors:  Joel B Nelson; Karim Fizazi; Kurt Miller; Celestia Higano; Judd W Moul; Hideyuki Akaza; Thomas Morris; Stuart McIntosh; Kristine Pemberton; Martin Gleave
Journal:  Cancer       Date:  2012-07-11       Impact factor: 6.860

6.  SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

Authors:  Oleg Tatarov; Thomas J Mitchell; Morag Seywright; Hing Y Leung; Valerie G Brunton; Joanne Edwards
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

7.  Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.

Authors:  T Sugatani; U M Alvarez; K A Hruska
Journal:  J Cell Biochem       Date:  2003-09-01       Impact factor: 4.429

8.  Decreased c-Src expression enhances osteoblast differentiation and bone formation.

Authors:  M Marzia; N A Sims; S Voit; S Migliaccio; A Taranta; S Bernardini; T Faraggiana; T Yoneda; G R Mundy; B F Boyce; R Baron; A Teti
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

9.  Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma.

Authors:  R Silbermann; M Bolzoni; P Storti; D Guasco; S Bonomini; D Zhou; J Wu; J L Anderson; J J Windle; F Aversa; G David Roodman; N Giuliani
Journal:  Leukemia       Date:  2013-12-26       Impact factor: 11.528

10.  Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.

Authors:  Amol Takalkar; Scott Adams; Vivek Subbiah
Journal:  Exp Hematol Oncol       Date:  2014-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.